The US Food and Drug Administration will not contest a recent court decision that concluded radiology contrast agents should be treated as devices and not drugs. The agency says it plans to begin treating a slew of such products as devices, but advises companies to pay their drug and generic user fees now and ask for reimbursement later.
The FDA issued a notice on 6 August that it will not contest the DC Circuit Court of Appeals’ determination that Genus Medical Technologies’ Vanilla SilQ barium sulfate imaging agents should be treated as devices. The agency had argued that it has broad regulatory authority to decide what is a drug versus a device, but the court disagreed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?